Atogepant

Short Description:

API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status 
Atogepant 1374248-81-3 Jun, 2027   Sep.28, 2035  estimated PV Completion – Apr, 2027

 

[Indication] 

1. For the preventive treatment of episodic migraine in adults.

2. For the preventive treatment of chronic migraine in adults.


Product Detail

Product Tags


  • Previous:
  • Next:

  • Write your message here and send it to us